Qualigen Therapeutics QLGN shares are trading higher on Wednesday, after the company signed an exclusive licensing agreement with the University of Louisville and it plans to develop its AS1411 for the treatment of coronavirus.
Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology.
Qualigen Therapeutics shares are trading up 6.12% at $5.72 at time of publication on Wednesday. The stock has a 52-week high of $31.75 and a 52-week low of $3.75.
Related Links:
UK Clears Gilead's Remdesivir For Some Coronavirus Patients
Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
